摩根中国生物医药混合(QDII)A(001984)财务指标
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 本期已实现收益 |
110,214,469.82 |
17,405,058.92 |
-115,931,232.74 |
-99,187,248.55 |
| 本期利润 |
166,400,391.22 |
127,598,314.05 |
-85,066,350.88 |
-82,142,675.08 |
| 加权平均基金份额本期利润 |
0.42 |
0.31 |
-0.19 |
-0.18 |
| 本期加权平均净值利润率(%) |
33.00 |
28.35 |
-18.95 |
-17.40 |
| 本期基金份额净值增长率(%) |
41.36 |
32.51 |
-16.17 |
-15.53 |
| 期末可供分配利润 |
-15,143,254.75 |
-113,940,068.48 |
-142,311,170.48 |
-132,753,444.44 |
| 期末可供分配基金份额利润 |
-0.04 |
-0.29 |
-0.33 |
-0.29 |
| 期末基金资产净值 |
484,044,436.71 |
497,813,674.07 |
408,562,376.14 |
432,044,867.15 |
| 期末基金份额净值 |
1.35 |
1.26 |
0.95 |
0.96 |
| 基金份额累计净值增长率(%) |
34.55 |
26.12 |
-4.82 |
-4.09 |
微信公众号
证券之星APP
基本资料
